Neurocysticercosis

Handbook of Clinical Neurology

Volumn 114, Issue , 2013, Pages 313-325

  Del Brutto, Oscar H ^a,b   Garcia, Hector H ^c,d  

^a UNIVERSIDAD ESPÍRITU SANTO   (Ecuador)

^b HOSPITAL CLÍNICA KENNEDY   (Ecuador)

^c INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^d Universidad Peruana Cayetano Heredia   (Peru)

Author keywords

Cysticercosis; Epilepsy; Neurocysticercosis; Pork tapeworm; Taenia solium

Indexed keywords

EID: 84879871441     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53490-3.00025-X     Document Type: Chapter

References (109)

1. Abba K., Ramaratnam S., Ranganathan L.N. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010, CD000215.
2. Allan J.C., Avila G., Garcia Noval J., et al. Immunodiagnosis of taeniasis by coproantigen detection. Parasitology 1990, 101:473-477.
3. Baranwal A.K., Singhi P.D., Khandelwal N., et al. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect Dis J 1998, 17:696-700.
4. Bern C., Garcia H.H., Evans C., et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999, 29:1203-1209.
5. Bianchin M.M., Velasco T.R., Takayanagui O.M., et al. Neurocysticercosis, mesial temporal lobe epilepsy, and hippocampal sclerosis: an association largely ignored. Lancet Neurol 2006, 5:20-21.
6. Bianchin M.M., Dal Pizzol A., Scotta Cabral L., et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 2010, 75:1028. author reply 1028-9.
7. Bittencourt P.R., Gracia C.M., Gorz A.M., et al. High-dose praziquantel for neurocysticercosis: efficacy and tolerability. Eur Neurol 1990, 30:229-234.
8. Bobes R.J., Hernandez M., Marquez C., et al. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop Med Int Health 2006, 11:943-950.
9. Brandt J.R., Geerts S., De Deken R., et al. A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosis. Int J Parasitol 1992, 22:471-477.
10. Bustos J.A., Pretell E.J., Llanos-Zavalaga F., et al. Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst. Clin Neurol Neurosurg 2006, 108:193-194.
11. Callacondo D, Garcia HH, Gonzales I et al., The Cysticercosis Working Group in Peru (in press). High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology.
12. Cantu C., Barinagarrementeria F. Cerebrovascular complications of neurocysticercosis: clinical and neuroimaging spectrum. Arch Neurol 1996, 53:233-239.
13. Carpio A., Santillan F., Leon P., et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents?. Arch Intern Med 1995, 155:1982-1988.
14. Castillo Y., Rodriguez S., Garcia H.H., et al. Urine antigen detection for the diagnosis of human neurocysticercosis. Am J Trop Med Hyg 2009, 80:379-383.
15. Ciampi de Andrade D., Rodrigues C.L., Abraham R., et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 2010, 74:1288-1295.
16. Ciftci E., Diaz-Marchan P.J., Hayman L.A. Intradural-extramedullary spinal cysticercosis: MR imaging findings. Comput Med Imaging Graph 1999, 23:161-164.
17. Corona T., Lugo R., Medina R., et al. Single-day praziquantel therapy for neurocysticercosis. N Engl J Med 1996, 334:125.
18. David S., Mathai E. Ocular cysticercosis: a review of 25 cases. J Assoc Physicians India 2000, 48:704-707.
19. Del Brutto O.H. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994, 44:1706-1709.
20. Del Brutto O.H. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J Neurol Neurosurg Psychiatry 1997, 62:659-661.
21. Del Brutto O.H. Infections and stroke. Handb Clin Neurol 2009, 93:851-872.
22. Del Brutto O.H., Del Brutto V.J. Changing pattern of neurocysticercosis in an urban endemic center (Guayaquil, Ecuador). J Neurol Sci 2012, 315:64-66.
23. Del Brutto O.H., Santibanez R., Noboa C.A., et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992, 42:389-392.
24. Del Brutto O.H., Sotelo J., Roman G.C. Neurocysticercosis 1997, A Clinical Handbook, Swets and Zeitliger, Lisse.
25. Del Brutto O.H., Campos X., Sanchez J., et al. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 1999, 52:1079-1081.
26. Del Brutto O.H., Rajshekhar V., White A.C., et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001, 57:177-183.
27. Del Brutto O.H., Santibanez R., Idrovo L., et al. Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia 2005, 46:583-587.
28. Del Brutto O.H., Roos K.L., Coffey C.S., et al. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006, 145:43-51.
29. Dixon H.B.F., Lipscomb F.M. Cysticercosis: An Analysis and Follow-up of 450 Cases. Special Report Series 1961, Vol. 299. Medical Research Council, London. H. M. s. S. Office (Ed.).
30. do Amaral L.L., Ferreira R.M., da Rocha A.J., et al. Neurocysticercosis: evaluation with advanced magnetic resonance techniques and atypical forms. Top Magn Reson Imaging 2005, 16:127-144.
31. Dumas J.L., Vusy J.M., Belin C. Parenchymal neurocysticercosis: follow up and staging by MRI. Neuroradiology 1997, 39:12-16.
32. Escobar A. The pathology of neurocysticercosis. Cysticercosis of the Central Nervous System 1983, 27-54. Charles C. Thomas, Springfield, IL. E. Palacios, J. Rodriguez-Carbajal, J.M. Taveras (Eds.).
33. Escobar A., Weidenheim K.M. The pathology of neurocysticercosis. Taenia solium Cysticercosis From Basic to Clinical Science 2002, 289-305. CABI Publishing, Oxon, UK. G. Singh, S. Prabhakar (Eds.).
34. Escobedo F., Penagos P., Rodriguez J., et al. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987, 147:738-741.
35. Espinoza B., Ruiz-Palacios G., Tovar A., et al. Characterization by enzyme-linked immunosorbent assay of the humoral immune response in patients with neurocysticercosis and its application in immunodiagnosis. J Clin Microbiol 1986, 24:536-541.
36. Estanol B., Corona T., Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry 1986, 49:1131-1134.
37. Fleury A., Carrillo-Mezo R., Flisser A., et al. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2010, 9:123-133.
38. Fleury A., Escobar A., Fragoso G., et al. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans R Soc Trop Med Hyg 2010, 104:243-250.
39. Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol 1994, 4:77-116.
40. Flisser A., Correa D. Neurocysticercosis may no longer be a public health problem in Mexico. PLoS Negl Trop Dis 2010, 4:e831.
41. Flisser A., Gauci C.G., Zoli A., et al. Induction of protection against porcine cysticercosis by vaccination with recombinant oncosphere antigens. Infect Immun 2004, 72:5292-5297.
42. Garcia H.H., Del Brutto O.H. Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Peru. Neurology 1999, 53:1582-1584.
43. Garcia H.H., Del Brutto O.H. Imaging findings in neurocysticercosis. Acta Trop 2003, 87:71-78.
44. Garcia H.H., Del Brutto O.H. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005, 4:653-661.
45. Garcia H.H., Gilman R.H., Horton J., et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 1997, 48:1421-1427.
46. Garcia H.H., Evans C.A., Nash T.E., et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002, 15:747-756.
47. Garcia H.H., Pretell E.J., Gilman R.H., et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004, 350:249-258.
48. Garcia H.H., Del Brutto O.H., Nash T.E., et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005, 72:3-9.
49. Garcia H.H., Gonzalez A.E., Gilman R.H., et al. Combined human and porcine mass chemotherapy for the control of T. solium. Am J Trop Med Hyg 2006, 74:850-855.
50. Garcia H.H., Gonzalez A.E., Del Brutto O.H., et al. Strategies for the elimination of taeniasis/cysticercosis. J Neurol Sci 2007, 262:153-157.
51. Garcia H.H., Gonzalez A.E., Rodriguez S., et al. Neurocysticercosis: unraveling the nature of the single cysticercal granuloma. Neurology 2010, 75:654-658.
52. Garcia H.H., Lescano A.G., Lanchote V., et al. Pharmacokinetics of Combined Treatment with Praziquantel and Albendazole in Neurocysticercosis. Br J Clin Pharmacol 2011.
53. Garcia H.H., Gonzalez A.E., Gilman R.H. Cysticercosis of the central nervous system: how should it be managed?. Curr Opin Infect Dis 2011, 24:423-427.
54. Gilman R.H., Del Brutto O.H., Garcia H.H., et al. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. The Cysticercosis Working Group in Peru. Neurology 2000, 55:1062.
55. Gogia S., Talukdar B., Choudhury V., et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 2003, 97:416-421.
56. Gongora-Rivera F., Soto-Hernandez J.L., Gonzalez Esquivel D., et al. Albendazole trial at 15 or 30mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006, 66:436-438.
57. Gonzalez A.E., Garcia H.H., Gilman R.H., et al. Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Am J Trop Med Hyg 1996, 54:391-394.
58. Gonzalez A.E., Gauci C.G., Barber D., et al. Vaccination of pigs to control human neurocysticercosis. Am J Trop Med Hyg 2005, 72:837-839.
59. Grove D. Taenia solium and taeniasis solium and cysticercosis. A History of Human Helmintology 1990, 355-383. C.A.B. International, Oxon. D. Grove (Ed.).
60. Guezala M.C., Rodriguez S., Zamora H., et al. Development of a species-specific coproantigen ELISA for human Taenia solium taeniasis. Am J Trop Med Hyg 2009, 81:433-437.
61. Guo D.M., Xie S.P., Jia J.P. Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003, 21:187-188.
62. Harrison L.J., Joshua G.W., Wright S.H., et al. Specific detection of circulating surface/secreted glycoproteins of viable cysticerci in Taenia saginata cysticercosis. Parasite Immunol 1989, 11:351-370.
63. Henneberg R. Die tierischen parasiten des zentralnervensystem. Handbuch der Neurologie 1912, 643-709. Verlag Von Julius Springer, Berlin. M. Lewandowsky (Ed.).
64. Kalra V., Dua T., Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 2003, 143:111-114.
65. Keilbach N.M., de Aluja A.S., Sarti-Gutierrez E. A programme to control taeniasis-cysticercosis (T. solium): experiences in a Mexican village. Acta Leiden 1989, 57:181-189.
66. Leite C.C., Jinkins J.R., Escobar B.E., et al. MR imaging of intramedullary and intradural-extramedullary spinal cysticercosis. AJR Am J Roentgenol 1997, 169:1713-1717.
67. Leshem E., Kliers I., Bakon M., et al. Neurocysticercosis in travelers: a nation-wide study in Israel. J Travel Med 2010, 18:191-197.
68. Lightowlers M.W. Eradication of Taenia solium cysticercosis: a role for vaccination of pigs. Int J Parasitol 2010, 40:1183-1192.
69. Lobato R.D., Lamas E., Portillo J.M., et al. Hydrocephalus in cerebral cysticercosis: pathogenic and therapeutic considerations. J Neurosurg 1981, 55:786-793.
70. Madigubba S., Vishwanath K., Reddy G., et al. Changing trends in ocular cysticercosis over two decades: an analysis of 118 surgically excised cysts. Indian J Med Microbiol 2007, 25:214-219.
71. Mahanty S., Garcia H.H. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol 2010, 91:172-184.
72. Medina M.T., Duron R.M., Martinez L., et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 2005, 46:124-131.
73. Mohanty A., Das S., Kolluri V.R., et al. Spinal extradural cysticercosis: a case report. Spinal Cord 1998, 36:285-287.
74. Montano S.M., Villaran M.V., Ylquimiche L., et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005, 65:229-233.
75. Nash T.E., Del Brutto O.H., Butman J.A., et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004, 62:1934-1938.
76. Nash T.E., Singh G., White A.C., et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006, 67:1120-1127.
77. Nash T.E., Pretell E.J., Lescano A.G., et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 2008, 7:1099-1105.
78. Ndimubanzi P.C., Carabin H., Budke C.M., et al. A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 2010, 4:e870.
79. Paterakis K.N., Kapsalaki E., Hadjigeorgiou G.M., et al. Primary spinal intradural extramedullary cysticercosis. Surg Neurol 2007, 68:309-311. discussion 312.
80. Pretell E.J., Garcia H.H., Gilman R.H., et al. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg 2001, 103:175-177. The Cysticercosis Working Group in Peru.
81. Proano J.V., Madrazo I., Avelar F., et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001, 345:879-885.
82. Quet F., Guerchet M., Pion S.D., et al. Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia 2010, 51:830-837.
83. Rajshekhar V. Etiology and management of single small CT lesions in patients with seizures: understanding a controversy. Acta Neurol Scand 1991, 84:465-470.
84. Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg 2010, 8:100-104.
85. Rajshekhar V., Chandy M.J. Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. Acta Neurol Scand 1997, 96:76-81.
86. Rangel R., Torres B., Del Bruto O., et al. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 1987, 36:387-392.
87. Rio de la Loza L.J., Meza E.L. Cysticercotic encephalitis: case report of miliary infestation in an encephalopathic fashion. Arch Neurol 2008, 65:276-277.
88. Rodriguez S., Dorny P., Tsang V.C., et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 2009, 199:1345-1352.
89. Rosas N., Sotelo J., Nieto D. ELISA in the diagnosis of neurocysticercosis. Arch Neurol 1986, 43:353-356.
90. Roy B., Verma S., Awasthi R., et al. Correlation of phase values with CT Hounsfield and R2* values in calcified neurocysticercosis. J Magn Reson Imaging 2011, 34:1060-1064.
91. Salinas R., Counsell C., Prasad K., et al. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 1999, 4:713-718.
92. Schantz P.M., Moore A.C., Munoz J.L., et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 1992, 327:692-695.
93. Serpa J.A., Graviss E.A., Kass J.S., et al. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 2010, 90:81-86.
94. Singh S., Gibikote S.V., Shyamkumar N.K. Isolated fourth ventricular cysticercus cyst: MR imaging in 4 cases with short literature review. Neurol India 2003, 51:394-396.
95. Singh G., Rajshekhar V., Murthy J.M., et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 2010, 75:2236-2245.
96. Sorvillo F., Wilkins P., Shafir S., et al. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 2010, 17:1-6.
97. Sotelo J., Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis: a long-term follow-up review of 92 cases. J Neurosurg 1987, 66:686-689.
98. Sotelo J., Escobedo F., Rodriguez-Carbajal J., et al. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 1984, 310:1001-1007.
99. Sotelo J., del Brutto O.H., Penagos P., et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990, 237:69-72.
100. Suastegui Roman R.A., Soto-Hernandez J.L., Sotelo J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996, 84:629-633.
101. Takayanagui O.M., Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel. Arch Neurol 1992, 49:290-294.
102. Torres-Corzo J.G., Tapia-Perez J.H., Vecchia R.R., et al. Endoscopic management of hydrocephalus due to neurocysticercosis. Clin Neurol Neurosurg 2010, 112:11-16.
103. Tsang V.C.W., Wilson M. Taenia solium cysticercosis, an under-recognized but serious public health problem. Parasitol Today 1995, 124-126.
104. Tsang V.C., Brand J.A., Boyer A.E. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989, 159:50-59.
105. White A.C. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med 2000, 51:187-206.
106. Willms K. Morphology and biochemistry of the pork tapeworm, Taenia solium. Curr Top Med Chem 2008, 8:375-382.
107. Wu Z., Mittal S., Kish K., et al. Identification of calcification with MRI using susceptibility-weighted imaging: a case study. J Magn Reson Imaging 2009, 29:177-182.
108. Yoshino K. Studies on the post-embryonal development of Taenia solium: III. On the development of Cysticercus cellulosae within the definitive intermediate host. J Med Assoc Formosa 1933, 32:166-169.
109. Zamora H., Castillo Y., Garcia H.H., et al. Drop in antigen levels following successful treatment of subarachnoid neurocysticercosis. Am J Trop Med Hyg 2005, 73:S41.